Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 4/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339453 | 0.86 | MCHR1 (0.38) | MCHR1FEN1 | |
| SCHEMBL24101666 | 0.86 | MCHR1 (0.38) | MCHR1FEN1 | |
| SCHEMBL30339398 | 0.82 | CYP1A2 (0.44) | MCHR1DDB1CRBNHTR6HRH1 | |
| SCHEMBL24101726 | 0.82 | CYP1A2 (0.44) | MCHR1DDB1CRBNHTR6HRH1 | |
| SCHEMBL25846111 | 0.80 | MCHR1 (0.52) | MCHR1HRH3HTR6CNR1 | |
| SCHEMBL968695 | 0.78 | PARP1 (0.47) | MCHR1ENPP2KDM4E | |
| SCHEMBL25846131 | 0.78 | DDB1 (0.48) | HRH3DDB1CRBNHTR6HRH1 | |
| SCHEMBL25846151 | 0.78 | MCHR1 (0.44) | MCHR1HRH3HTR6HRH1CNR1 | |
| SCHEMBL26017344 | 0.74 | DDB1 (0.46) | DDB1CRBNHTR6HRH1ENPP2 | |
| SCHEMBL24101662 | 0.72 | HTR2A (0.59) | MCHR1DDB1CRBNHTR6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227453-A1 | TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227453-A1 | TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF | GAP43, GRIN2A, GRIN2C | MCHR1 320/4885HRH3 1112/4885DDB1 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.